Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005267 | 0.88 | MAPT (0.54) | CNR2THRBGAAL3MBTL1KMT2A | |
| SCHEMBL14030757 | 0.86 | RAB9A (0.53) | CNR2LMNAGAAKMT2A | |
| SCHEMBL14030749 | 0.84 | ACACB (0.43) | CNR2LMNAGAAHPGDEGLN1 | |
| SCHEMBL14005266 | 0.83 | RAB9A (0.55) | CNR2THRBHPGDKMT2ARXFP1 | |
| SCHEMBL4745657 | 0.82 | CNR2 (0.76) | CNR2LMNACYP1A2CYP2C19 | |
| SCHEMBL14030760 | 0.81 | KMT2A (0.46) | GAAHPGDKMT2A | |
| SCHEMBL14030761 | 0.78 | EGLN1 (0.39) | CNR2THRBKMT2AEGLN1 | |
| SCHEMBL14005262 | 0.77 | HPGDS (0.67) | HPGDL3MBTL1HPGDS | |
| SCHEMBL14030766 | 0.76 | HDAC1 (0.46) | — | |
| SCHEMBL14005263 | 0.71 | CNR2 (0.58) | CNR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | CNR2 496/4885THRB 1846/4885LMNA 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.